BEVbiotics develops precision gut‑health therapies using bacterial extracellular vesicles (BEVs), a cell‑free platform that delivers targeted, predictable payloads to the intestinal microbiome. By replacing traditional live probiotics with these natural nanocarriers, the company aims to provide more consistent and potent effects for improving overall health and performance.
Funding
Funding not disclosed
Founders
Product
Problem
Current probiotic products rely on live bacterial strains that are unstable, difficult to standardize, and often produce inconsistent effects on gut health, limiting their therapeutic reliability.
Solution
BEVbiotics replaces live microbes with engineered bacterial extracellular vesicles (BEVs), a cell‑free platform that delivers defined, potent bioactive payloads directly to the intestinal microbiome. The vesicles are manufactured under controlled conditions, ensuring precise dosing and reproducible activity. By targeting the gut environment with these stable nanocarriers, the company provides a scalable therapy that can modulate microbiome function and improve physiological performance with predictable outcomes.
Target Audience
Primary customers are pharmaceutical and nutraceutical developers seeking reliable gut‑health interventions, as well as clinical researchers focused on microbiome‑based therapies.
Features
- Cell‑free bacterial extracellular vesicles engineered to carry specific therapeutic molecules
- Precise, reproducible dosing enabled by scalable biomanufacturing processes
- Direct delivery of payloads to the gut lumen without the need for live bacterial colonization
- Enhanced stability and shelf‑life compared to traditional probiotic formulations
- Ability to customize vesicle cargo for targeted modulation of microbiome pathways